Evidence map›Paper›PMID 33326874›Full record

ArticleInternational journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases2021

Covid-19 and blood groups: ABO antibody levels may also matter.

Marie Deleers, Adrien Breiman, Valéry Daubie, Carine Maggetto, Isabelle Barreau, Tatiana Besse, Béatrice Clémenceau, Nathalie Ruvoën-Clouet, Jean-François Fils, Evelyne Maillart and 9 more

Open access · goldAbstract read
In one paragraph

Article in International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 1 pooled it
8.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 1 synthesis or guideline pooled it, 77 citations in OpenAlex.

  1. Mucosal immune response in biology, disease prevention and treatment.Signal transduction and targeted therapy · 2025
    Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Immunoglobulin Class Profiles of ABO Antibodies in Saliva and Serum of Healthy Individuals.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2023
    Article
  9. Review
  10. Article
  11. Blood-Type-A is a COVID-19 infection and hospitalization risk in a Turkish cohort.Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine · 2023
    Article
  12. Article
  13. Article
  14. COVID-19 host genetics and ABO blood group susceptibility.Cambridge prisms. Precision medicine · 2023
    Review
  15. Observational
  16. Article
  17. Article
  18. Review
  19. ABO and Rh blood groups, demographics, and comorbidities in COVID-19 related deaths: A retrospective study in Split-Dalmatia County, Croatia.Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis · 2022
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 3 institutions in 2 countries.

Marie DeleersDepartment of Transfusion, CHU Brugmann, Université Libre de Bruxelles (ULB), Brussels, Belgium; Laboratory of Immunology, LHUB-ULB, Brussels, Belgium. Electronic address: Marie.deleers@chu-brugmann.be.
Adrien BreimanUniversité de Nantes, INSERM, CRCINA, Nantes, France; CHU de Nantes, Nantes, France.
Valéry DaubieLaboratory of Immunology, LHUB-ULB, Brussels, Belgium.
Carine MaggettoDepartment of Transfusion, CHU Brugmann, Université Libre de Bruxelles (ULB), Brussels, Belgium.
Isabelle BarreauDepartment of Transfusion, CHU Brugmann, Université Libre de Bruxelles (ULB), Brussels, Belgium; Laboratory of Immunology, LHUB-ULB, Brussels, Belgium.
Tatiana BesseDepartment of Clinical Research, CHU Brugmann, Université Libre de Bruxelles (ULB), Brussels, Belgium.
Béatrice ClémenceauUniversité de Nantes, INSERM, CRCINA, Nantes, France; CHU de Nantes, Nantes, France.
Nathalie Ruvoën-ClouetUniversité de Nantes, INSERM, CRCINA, Nantes, France; Oniris, Ecole Nationale Vétérinaire, Agroalimentaire et de l'Alimentation, Nantes, France.
Jean-François FilsArs Statistica, Boulevard des Archers 40, 1400, Nivelles, Belgium.
Evelyne MaillartDepartment of Infectious Diseases, CHU Brugmann, Université Libre de Bruxelles (ULB), Brussels, Belgium.
Virginie DoyenImmuno-Allergology Clinic, CHU Brugmann, Université Libre de Bruxelles (ULB), Brussels, Belgium; Laboratory of Translational Research, CHU Brugmann, Université Libre de Bruxelles (ULB), Brussels, Belgium.
Bhavna MahadebLaboratory of Microbiology, LHUB-ULB, Brussels, Belgium.
Jacques C JaniDepartment of Obstetrics and Gynaecology, CHU Brugmann, Université Libre de Bruxelles (ULB), Brussels, Belgium.
Philippe Van der LindenDepartment of Anesthesiology, CHU Brugmann, Université Libre de Bruxelles (ULB), Belgium.
Mieke M CannieDepartment of Radiology, CHU Brugmann, Université Libre de Bruxelles (ULB), Brussels, Belgium.
Nabil HayefDepartment of Pharmacy (Clinical Trials), CHU Brugmann, Université Libre de Bruxelles (ULB), Brussels, Belgium.
Francis CorazzaLaboratory of Immunology, LHUB-ULB, Brussels, Belgium; Laboratory of Translational Research, CHU Brugmann, Université Libre de Bruxelles (ULB), Brussels, Belgium.
Jacques Le PenduUniversité de Nantes, INSERM, CRCINA, Nantes, France.
Hanane El KenzDepartment of Transfusion, CHU Brugmann, Université Libre de Bruxelles (ULB), Brussels, Belgium; Laboratory of Immunology, LHUB-ULB, Brussels, Belgium.
Université Libre de Bruxelles · BEInserm · FRStatistics Belgium · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSusceptibility to Covid-19 has been found to be associated with the ABO blood group, with O type individuals being at a lower risk. However, the underlying mechanism has not been elucidated. Here, we aimed to test the hypothesis that Covid-19 patients might have lower levels of ABO antibodies than non-infected individuals as they could offer some degree of protection.

methodsAfter showing that the viral spike protein harbors the ABO glycan epitopes when produced by cells expressing the relevant glycosyltransferases, like upper respiratory tract epithelial cells, we enrolled 290 patients with Covid-19 and 276 asymptomatic controls to compare their levels of natural ABO blood group antibodies.

resultsWe found significantly lower IgM anti-A + anti-B agglutination scores in blood group O patients (76.93 vs 88.29, P-value = 0.034) and lower levels of anti-B (24.93 vs 30.40, P-value = 0.028) and anti-A antibodies (28.56 vs 36.50, P-value = 0.048) in blood group A and blood group B patients, respectively, compared to controls.

conclusionIn this study, we showed that ABO antibody levels are significantly lower in Covid-19 patients compared to controls. These findings could indicate that patients with low levels of ABO antibodies are at higher risk of being infected.

Indexed as

ABO Blood-Group SystemAdultAgedAged, 80 and overAntibodiesCOVID-19Disease SusceptibilityEpithelial CellsEpitopesFemaleGalactosyltransferasesHumansImmunoglobulin MMaleMiddle AgedPolysaccharidesABO Blood-Group SystemABO protein, humanAntibodiesEpitopesGalactosyltransferasesImmunoglobulin MPolysaccharidesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2ABO antibodiesABO antibody levelsABO blood groupCovid-19Covid-19 infection risk

Identifiers

PMID33326874
PMCPMC7832075
OpenAlexW3112225305

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.